drugset / Trial / NCT03680521
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
Timeline
- Start
- 2018-10-10
- Primary completion
- 2020-04-27
- Completion
- 2023-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Sitravatinib | Small molecule | — | Oral |